Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET
Company Participants
Ioana Hone – Head of Investor Relations
Brian Culley – Chief Executive Officer
Jill Howe – Chief Financial Officer
Conference Call Participants
William Wood – B. Riley Securities
Joseph Pantginis – H.C. Wainwright & Co., LLC
Jack Allen – Robert W. Baird & Co.
Michael Okunewitch – Maxim Group, LLC
Albert Lowe – Craig-Hallum Capital Group
Sean McCutcheon – Raymond James
Operator
Welcome to the Lineage Cell Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen only mode. An audio webcast of this call is available on the Investors section of Lineage website at www.Lineagecell.com. This call is subject to copyright and is the property of Lineage and recordings, reproductions or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today’s call is being recorded.
I would now like to introduce your host for today’s call, Ioana Hone, Head of Investor relations at Lineage. Ms. Hone, please go ahead.
Ioana Hone
Thank you. John Good afternoon and thank you for joining us. A press release reporting our third quarter 2024 financial results was issued earlier today, November 14, 2024 and can be found on the Investors section of our website. Please note that today’s remarks and responses to your questions reflect management’s views as of today only and will contain forward looking statements within the meaning of Federal Securities Laws. Statements made during this discussion that are not statements of historical fact should be considered forward looking statements which are subject to significant risks and uncertainties. The company’s actual results or performance may differ materially from the expectations indicated by such forward looking statements. For a discussion of certain factors that could cause the company’s results
